Company intelligence / Profile preview

HRH Pharmaceuticals Limited

Kolkata, West Bengal, India

Ownership: Private
Development stage: Commercial

Overview

HRH Pharmaceuticals Limited has developed Azvudine, which received approval in China on July 21, 2021 for COVID-19 treatment. The company has completed two Phase 3 clinical trials evaluating the safety and efficacy of Azvudine in COVID-19 patients[1].

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

azvudine

Commercial

Indications: COVID-19, HIV Infections, Acquired Immunodeficiency Syndrome

Partnerships

Genuine Biotech LimitedZhengzhou University

Beyond the preview

Go deeper on HRH Pharmaceuticals Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRH Pharmaceuticals Limited.

Explore the full profile